Immunomodulatory effects of ambroxol on airway hyperresponsiveness and inflammation

Katsuyuki Takeda, Nobuaki Miyahara, Shigeki Matsubara, Christian Taube, Kenichi Kitamura, Astushi Hirano, Mitsune Tanimoto, Erwin W. Gelfand

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ambroxol is used in COPD and asthma to increase mucociliary clearance and regulate surfactant levels, perhaps through anti-oxidant and anti-inflammatory activities. To determine the role and effect of ambroxol in an experimental model of asthma, BALB/c mice were sensitized to ovalbumin (OVA) followed by 3 days of challenge. Airway hyperresponsiveness (AHR), lung cell composition and histology, and cytokine and protein carbonyl levels in bronchoalveolar lavage (BAL) fluid were determined. Ambroxol was administered either before the first OVA challenge or was begun after the last allergen challenge. Cytokine production levels from lung mononuclear cells (Lung MNCs) or alveolar macrophages (AM) were also determined. Administration of ambroxol prior to challenge suppressed AHR, airway eosinophilia, goblet cell metaplasia, and reduced inflammation in subepithelial regions. When given after challenge, AHR was suppressed but without effects on eosinophil numbers. Levels of IL-5 and IL-13 in BAL fluid were decreased when the drug was given prior to challenge; when given after challenge, increased levels of IL-10 and IL-12 were detected. Decreased levels of protein carbonyls were detected in BAL fluid following ambroxol treatment after challenge. In vitro, ambroxol increased levels of IL-10, IFN-γ, and IL-12 from Lung MNCs and AM, whereas IL-4, IL-5, and IL-13 production was not altered. Taken together, ambroxol was effective in preventing AHR and airway inflammation through upregulation of Th1 cytokines and protection from oxidative stress in the airways.

Original languageEnglish
Pages (from-to)165-175
Number of pages11
JournalImmune Network
Volume16
Issue number3
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Ambroxol
Inflammation
Bronchoalveolar Lavage Fluid
Interleukin-13
Interleukin-5
Ovalbumin
Alveolar Macrophages
Interleukin-12
Cytokines
Interleukin-10
Lung
Asthma
Mucociliary Clearance
Goblet Cells
Metaplasia
Eosinophilia
Eosinophils
Oxidants
Surface-Active Agents
Interleukin-4

Keywords

  • Airway hyperresponsiveness
  • Ambroxol
  • Eosinophils
  • Neutrophils

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology

Cite this

Takeda, K., Miyahara, N., Matsubara, S., Taube, C., Kitamura, K., Hirano, A., ... Gelfand, E. W. (2016). Immunomodulatory effects of ambroxol on airway hyperresponsiveness and inflammation. Immune Network, 16(3), 165-175. https://doi.org/10.4110/in.2016.16.3.165

Immunomodulatory effects of ambroxol on airway hyperresponsiveness and inflammation. / Takeda, Katsuyuki; Miyahara, Nobuaki; Matsubara, Shigeki; Taube, Christian; Kitamura, Kenichi; Hirano, Astushi; Tanimoto, Mitsune; Gelfand, Erwin W.

In: Immune Network, Vol. 16, No. 3, 2016, p. 165-175.

Research output: Contribution to journalArticle

Takeda, K, Miyahara, N, Matsubara, S, Taube, C, Kitamura, K, Hirano, A, Tanimoto, M & Gelfand, EW 2016, 'Immunomodulatory effects of ambroxol on airway hyperresponsiveness and inflammation', Immune Network, vol. 16, no. 3, pp. 165-175. https://doi.org/10.4110/in.2016.16.3.165
Takeda, Katsuyuki ; Miyahara, Nobuaki ; Matsubara, Shigeki ; Taube, Christian ; Kitamura, Kenichi ; Hirano, Astushi ; Tanimoto, Mitsune ; Gelfand, Erwin W. / Immunomodulatory effects of ambroxol on airway hyperresponsiveness and inflammation. In: Immune Network. 2016 ; Vol. 16, No. 3. pp. 165-175.
@article{1b6f90d2e2ac4bc886262b266f4275b3,
title = "Immunomodulatory effects of ambroxol on airway hyperresponsiveness and inflammation",
abstract = "Ambroxol is used in COPD and asthma to increase mucociliary clearance and regulate surfactant levels, perhaps through anti-oxidant and anti-inflammatory activities. To determine the role and effect of ambroxol in an experimental model of asthma, BALB/c mice were sensitized to ovalbumin (OVA) followed by 3 days of challenge. Airway hyperresponsiveness (AHR), lung cell composition and histology, and cytokine and protein carbonyl levels in bronchoalveolar lavage (BAL) fluid were determined. Ambroxol was administered either before the first OVA challenge or was begun after the last allergen challenge. Cytokine production levels from lung mononuclear cells (Lung MNCs) or alveolar macrophages (AM) were also determined. Administration of ambroxol prior to challenge suppressed AHR, airway eosinophilia, goblet cell metaplasia, and reduced inflammation in subepithelial regions. When given after challenge, AHR was suppressed but without effects on eosinophil numbers. Levels of IL-5 and IL-13 in BAL fluid were decreased when the drug was given prior to challenge; when given after challenge, increased levels of IL-10 and IL-12 were detected. Decreased levels of protein carbonyls were detected in BAL fluid following ambroxol treatment after challenge. In vitro, ambroxol increased levels of IL-10, IFN-γ, and IL-12 from Lung MNCs and AM, whereas IL-4, IL-5, and IL-13 production was not altered. Taken together, ambroxol was effective in preventing AHR and airway inflammation through upregulation of Th1 cytokines and protection from oxidative stress in the airways.",
keywords = "Airway hyperresponsiveness, Ambroxol, Eosinophils, Neutrophils",
author = "Katsuyuki Takeda and Nobuaki Miyahara and Shigeki Matsubara and Christian Taube and Kenichi Kitamura and Astushi Hirano and Mitsune Tanimoto and Gelfand, {Erwin W.}",
year = "2016",
doi = "10.4110/in.2016.16.3.165",
language = "English",
volume = "16",
pages = "165--175",
journal = "Immune Network",
issn = "1598-2629",
publisher = "Korean Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Immunomodulatory effects of ambroxol on airway hyperresponsiveness and inflammation

AU - Takeda, Katsuyuki

AU - Miyahara, Nobuaki

AU - Matsubara, Shigeki

AU - Taube, Christian

AU - Kitamura, Kenichi

AU - Hirano, Astushi

AU - Tanimoto, Mitsune

AU - Gelfand, Erwin W.

PY - 2016

Y1 - 2016

N2 - Ambroxol is used in COPD and asthma to increase mucociliary clearance and regulate surfactant levels, perhaps through anti-oxidant and anti-inflammatory activities. To determine the role and effect of ambroxol in an experimental model of asthma, BALB/c mice were sensitized to ovalbumin (OVA) followed by 3 days of challenge. Airway hyperresponsiveness (AHR), lung cell composition and histology, and cytokine and protein carbonyl levels in bronchoalveolar lavage (BAL) fluid were determined. Ambroxol was administered either before the first OVA challenge or was begun after the last allergen challenge. Cytokine production levels from lung mononuclear cells (Lung MNCs) or alveolar macrophages (AM) were also determined. Administration of ambroxol prior to challenge suppressed AHR, airway eosinophilia, goblet cell metaplasia, and reduced inflammation in subepithelial regions. When given after challenge, AHR was suppressed but without effects on eosinophil numbers. Levels of IL-5 and IL-13 in BAL fluid were decreased when the drug was given prior to challenge; when given after challenge, increased levels of IL-10 and IL-12 were detected. Decreased levels of protein carbonyls were detected in BAL fluid following ambroxol treatment after challenge. In vitro, ambroxol increased levels of IL-10, IFN-γ, and IL-12 from Lung MNCs and AM, whereas IL-4, IL-5, and IL-13 production was not altered. Taken together, ambroxol was effective in preventing AHR and airway inflammation through upregulation of Th1 cytokines and protection from oxidative stress in the airways.

AB - Ambroxol is used in COPD and asthma to increase mucociliary clearance and regulate surfactant levels, perhaps through anti-oxidant and anti-inflammatory activities. To determine the role and effect of ambroxol in an experimental model of asthma, BALB/c mice were sensitized to ovalbumin (OVA) followed by 3 days of challenge. Airway hyperresponsiveness (AHR), lung cell composition and histology, and cytokine and protein carbonyl levels in bronchoalveolar lavage (BAL) fluid were determined. Ambroxol was administered either before the first OVA challenge or was begun after the last allergen challenge. Cytokine production levels from lung mononuclear cells (Lung MNCs) or alveolar macrophages (AM) were also determined. Administration of ambroxol prior to challenge suppressed AHR, airway eosinophilia, goblet cell metaplasia, and reduced inflammation in subepithelial regions. When given after challenge, AHR was suppressed but without effects on eosinophil numbers. Levels of IL-5 and IL-13 in BAL fluid were decreased when the drug was given prior to challenge; when given after challenge, increased levels of IL-10 and IL-12 were detected. Decreased levels of protein carbonyls were detected in BAL fluid following ambroxol treatment after challenge. In vitro, ambroxol increased levels of IL-10, IFN-γ, and IL-12 from Lung MNCs and AM, whereas IL-4, IL-5, and IL-13 production was not altered. Taken together, ambroxol was effective in preventing AHR and airway inflammation through upregulation of Th1 cytokines and protection from oxidative stress in the airways.

KW - Airway hyperresponsiveness

KW - Ambroxol

KW - Eosinophils

KW - Neutrophils

UR - http://www.scopus.com/inward/record.url?scp=85020118193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020118193&partnerID=8YFLogxK

U2 - 10.4110/in.2016.16.3.165

DO - 10.4110/in.2016.16.3.165

M3 - Article

VL - 16

SP - 165

EP - 175

JO - Immune Network

JF - Immune Network

SN - 1598-2629

IS - 3

ER -